These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 2850890)
1. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development. Farrar WL; Harel-Bellan A; Ferris DK Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD4+ T cell function by the HIV envelope protein, gp120. Diamond DC; Sleckman BP; Gregory T; Lasky LA; Greenstein JL; Burakoff SJ J Immunol; 1988 Dec; 141(11):3715-7. PubMed ID: 2846691 [TBL] [Abstract][Full Text] [Related]
3. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307 [TBL] [Abstract][Full Text] [Related]
4. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Landau NR; Warton M; Littman DR Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352 [TBL] [Abstract][Full Text] [Related]
5. Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120. Siliciano RF; Knall C; Lawton T; Berman P; Gregory T; Reinherz EL J Immunol; 1989 Mar; 142(5):1506-11. PubMed ID: 2537355 [TBL] [Abstract][Full Text] [Related]
6. HIV infection is blocked in vitro by recombinant soluble CD4. Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022 [TBL] [Abstract][Full Text] [Related]
8. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Hussey RE; Richardson NE; Kowalski M; Brown NR; Chang HC; Siliciano RF; Dorfman T; Walker B; Sodroski J; Reinherz EL Nature; 1988 Jan; 331(6151):78-81. PubMed ID: 2829023 [TBL] [Abstract][Full Text] [Related]
9. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Clayton LK; Sieh M; Pious DA; Reinherz EL Nature; 1989 Jun; 339(6225):548-51. PubMed ID: 2543930 [TBL] [Abstract][Full Text] [Related]
10. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Traunecker A; Lüke W; Karjalainen K Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024 [TBL] [Abstract][Full Text] [Related]
11. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567 [TBL] [Abstract][Full Text] [Related]
12. Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry. Corbeau P; Benkirane M; Weil R; David C; Emiliani S; Olive D; Mawas C; Serre A; Devaux C J Immunol; 1993 Jan; 150(1):290-301. PubMed ID: 7678031 [TBL] [Abstract][Full Text] [Related]
13. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Delézay O; Hammache D; Fantini J; Yahi N Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929 [TBL] [Abstract][Full Text] [Related]
14. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140 [TBL] [Abstract][Full Text] [Related]
15. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516 [TBL] [Abstract][Full Text] [Related]
16. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809 [TBL] [Abstract][Full Text] [Related]
17. HIV env glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation. Beretta A; Grassi F; Pelagi M; Clivio A; Parravicini C; Giovinazzo G; Andronico F; Lopalco L; Verani P; Buttò S Eur J Immunol; 1987 Dec; 17(12):1793-8. PubMed ID: 2446880 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713 [TBL] [Abstract][Full Text] [Related]
19. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Clayton LK; Hussey RE; Steinbrich R; Ramachandran H; Husain Y; Reinherz EL Nature; 1988 Sep; 335(6188):363-6. PubMed ID: 2843773 [TBL] [Abstract][Full Text] [Related]
20. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. Mann DL; Lasane F; Popovic M; Arthur LO; Robey WG; Blattner WA; Newman MJ J Immunol; 1987 Apr; 138(8):2640-4. PubMed ID: 3031162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]